ID   P53_RAT                 Reviewed;         391 AA.
AC   P10361; O09168; Q4KMA9; Q66HM0;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1989, sequence version 1.
DT   02-OCT-2024, entry version 242.
DE   RecName: Full=Cellular tumor antigen p53;
DE   AltName: Full=Tumor suppressor p53;
GN   Name=Tp53; Synonyms=P53;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3060862; DOI=10.1093/nar/16.23.11384;
RA   Soussi T.;
RT   "Nucleotide sequence of a cDNA encoding the rat p53 nuclear oncoprotein.";
RL   Nucleic Acids Res. 16:11384-11384(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8441680; DOI=10.1093/nar/21.3.713;
RA   Hulla J.E., Schneider R.P.;
RT   "Structure of the rat p53 tumor suppressor gene.";
RL   Nucleic Acids Res. 21:713-717(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley;
RX   PubMed=9278438; DOI=10.1074/jbc.272.36.22776;
RA   Mathupala S.P., Heese C., Pedersen P.L.;
RT   "Glucose catabolism in cancer cells. The type II hexokinase promoter
RT   contains functionally active response elements for the tumor suppressor
RT   p53.";
RL   J. Biol. Chem. 272:22776-22780(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart, and Thymus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH HSP90AB1.
RC   TISSUE=Embryo;
RX   PubMed=8663025; DOI=10.1074/jbc.271.25.15084;
RA   Sepehrnia B., Paz I.B., Dasgupta G., Momand J.;
RT   "Heat shock protein 84 forms a complex with mutant p53 protein
RT   predominantly within a cytoplasmic compartment of the cell.";
RL   J. Biol. Chem. 271:15084-15090(1996).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=22726440; DOI=10.1016/j.cell.2012.05.014;
RA   Vaseva A.V., Marchenko N.D., Ji K., Tsirka S.E., Holzmann S., Moll U.M.;
RT   "p53 opens the mitochondrial permeability transition pore to trigger
RT   necrosis.";
RL   Cell 149:1536-1548(2012).
CC   -!- FUNCTION: Multifunctional transcription factor that induces cell cycle
CC       arrest, DNA repair or apoptosis upon binding to its target DNA
CC       sequence. Acts as a tumor suppressor in many tumor types; induces
CC       growth arrest or apoptosis depending on the physiological circumstances
CC       and cell type. Negatively regulates cell division by controlling
CC       expression of a set of genes required for this process. One of the
CC       activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis
CC       induction seems to be mediated either by stimulation of BAX and FAS
CC       antigen expression, or by repression of Bcl-2 expression. Its pro-
CC       apoptotic activity is activated via its interaction with PPP1R13B/ASPP1
CC       or TP53BP2/ASPP2 (By similarity). However, this activity is inhibited
CC       when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced
CC       by PPP1R13L/iASPP (By similarity). In cooperation with mitochondrial
CC       PPIF is involved in activating oxidative stress-induced necrosis; the
CC       function is largely independent of transcription. Prevents CDK7 kinase
CC       activity when associated to CAK complex in response to DNA damage, thus
CC       stopping cell cycle progression. Induces the transcription of long
CC       intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-
CC       p21 participates in TP53-dependent transcriptional repression leading
CC       to apoptosis and seems to have an effect on cell-cycle regulation.
CC       Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated
CC       transcriptional activation of PER2. {ECO:0000250|UniProtKB:P02340,
CC       ECO:0000250|UniProtKB:P04637}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250};
CC   -!- SUBUNIT: Forms homodimers and homotetramers (By similarity). Binds DNA
CC       as a homotetramer. Interacts with AXIN1. Probably part of a complex
CC       consisting of TP53, HIPK2 and AXIN1 (By similarity). Interacts with
CC       histone acetyltransferases EP300 and methyltransferases HRMT1L2 and
CC       CARM1, and recruits them to promoters. Interacts (via C-terminus) with
CC       TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this
CC       interaction may be indirect. Found in a complex with CABLES1 and TP73.
CC       Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX.
CC       Interacts with USP7 and SYVN1. Interacts with HSP90AB1
CC       (PubMed:8663025). Interacts with CHD8; leading to recruit histone H1
CC       and prevent transactivation activity (By similarity). Interacts with
CC       ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts
CC       with YWHAZ; the interaction enhances TP53 transcriptional activity.
CC       Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction.
CC       Interacts (via DNA-binding domain) with MAML1 (via N-terminus).
CC       Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts
CC       with MDM2; leading to ubiquitination and proteasomal degradation of
CC       TP53. Directly interacts with FBXO42; leading to ubiquitination and
CC       degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with
CC       the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-
CC       dependent inhibition of cell proliferation. Interacts with PPP2R2A.
CC       Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when
CC       monomethylated at Lys-380) with L3MBTL1. Interacts with GRK5. Binds to
CC       the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage.
CC       Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and
CC       NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes
CC       ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes
CC       ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the
CC       association implicates preferentially tetrameric TP53, is induced by
CC       oxidative stress and is impaired by cyclosporin A (CsA). Interacts with
CC       SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated
CC       ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with
CC       UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via
CC       DNA-binding domain) with ZNF385A; the interaction is direct and
CC       enhances p53/TP53 transactivation functions on cell-cycle arrest target
CC       genes, resulting in growth arrest. Interacts with ANKRD2. Interacts
CC       with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts
CC       with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts
CC       with MORC3. Interacts (via C-terminus) with POU4F2 (via C-terminus).
CC       Interacts (via oligomerization region) with NOP53; the interaction is
CC       direct and may prevent the MDM2-mediated proteasomal degradation of
CC       TP53. Interacts with AFG1L; mediates mitochondrial translocation of
CC       TP53. Interacts with UBD (By similarity). Interacts with TAF6 (By
CC       similarity). Binds DNA as a homotetramer. Interacts with AXIN1.
CC       Probably part of a complex consisting of TP53, HIPK2 and AXIN1.
CC       Interacts with histone acetyltransferases EP300 and methyltransferases
CC       HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C-
CC       terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts
CC       with ING4; this interaction may be indirect. Found in a complex with
CC       CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts
CC       with WWOX. Interacts with USP7 and SYVN1. Interacts with HSP90AB1.
CC       Interacts with CHD8; leading to recruit histone H1 and prevent
CC       transactivation activity. Interacts with ARMC10, BANP, CDKN2AIP, NUAK1,
CC       STK11/LKB1, UHRF2 and E4F. Interacts with YWHAZ; the interaction
CC       enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on
CC       'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain)
CC       with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML
CC       (via C-terminus). Interacts with MDM2; leading to ubiquitination and
CC       proteasomal degradation of TP53. Directly interacts with FBXO42;
CC       leading to ubiquitination and degradation of TP53. Interacts
CC       (phosphorylated at Ser-18 by ATM) with the phosphatase PP2A-PPP2R5C
CC       holoenzyme; regulates stress-induced TP53-dependent inhibition of cell
CC       proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7
CC       and TRIM24. Interacts (when monomethylated at Lys-379) with L3MBTL1.
CC       Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1)
CC       in response to DNA damage. Interacts with CDK5 in neurons. Interacts
CC       with AURKB, SETD2, UHRF2 and NOC2L. Interacts (via N-terminus) with
CC       PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with
CC       PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG.
CC       Interacts with PPIF; the association implicates preferentially
CC       tetrameric TP53, is induced by oxidative stress and is impaired by
CC       cyclosporin A (CsA). Interacts with SNAI1; the interaction induces
CC       SNAI1 degradation via MDM2-mediated ubiquitination and inhibits SNAI1-
CC       induced cell invasion. Interacts with UBC9. Interacts with ZNF385B; the
CC       interaction is direct. Interacts (via DNA-binding domain) with ZNF385A;
CC       the interaction is direct and enhances p53/TP53 transactivation
CC       functions on cell-cycle arrest target genes, resulting in growth arrest
CC       (By similarity). Interacts with ANKRD2. Interacts with RFFL and RNF34;
CC       involved in p53/TP53 ubiquitination. Interacts with MTA1 and COP1.
CC       Interacts with CCAR2 (via N-terminus). Interacts with MORC3. Interacts
CC       (via C-terminus) with POU4F2 (via C-terminus). Interacts (via
CC       oligomerization region) with NOP53; the interaction is direct and may
CC       prevent the MDM2-mediated proteasomal degradation of TP53. Interacts
CC       with AFG1L; mediates mitochondrial translocation of TP53. Interacts
CC       with UBD (By similarity). Interacts with C10orf90/FATS; the interaction
CC       inhibits binding of TP53 and MDM2 (By similarity). Interacts with
CC       NUPR1; interaction is stress-dependent. Forms a complex with EP300 and
CC       NUPR1; this complex binds CDKN1A promoter leading to transcriptional
CC       induction of CDKN1A (By similarity). Interacts with PRMT5 in response
CC       to DNA damage; the interaction is TTC5/STRAP dependent (By similarity).
CC       Interacts with PPP1R13L (via SH3 domain and ANK repeats); the
CC       interaction inhibits pro-apoptotic activity of p53/TP53 (By
CC       similarity). Interacts with PPP1R13B/ASPP1 and TP53BP2/ASPP2; the
CC       interactions promotes pro-apoptotic activity (By similarity). When
CC       phosphorylated at Ser-15, interacts with DDX3X and gamma-tubulin (By
CC       similarity). Interacts with KAT7/HBO1; leading to inhibit histone
CC       acetyltransferase activity of KAT7/HBO1 (By similarity). Interacts (via
CC       N-terminus) with E3 ubiquitin-protein ligase MUL1; the interaction
CC       results in ubiquitination of cytoplasmic TP53 at Lys-24 and subsequent
CC       proteasomal degradation (By similarity). Interacts with S100A4; this
CC       interaction promotes TP53 degradation (By similarity). Interacts with
CC       TTC5/STRAP; the interaction may result in increased mitochondrial-
CC       dependent apoptosis (By similarity). Interacts with NQO1; this
CC       interaction is NADH-dependent, stabilizes TP53 in response to oxidative
CC       stress and protects it from ubiquitin-independent degradation by the
CC       20S proteasome (By similarity). Interacts with DAZAP2 at TP53 target
CC       gene promoters; the interaction is triggered by DNA damage and leads to
CC       modulation of the expression of a subset of TP53 target genes, reducing
CC       DNA damage-induced cell death by limiting the expression of cell death-
CC       mediating TP53 target genes (By similarity). Interacts (via N-terminus)
CC       with ZNF768 (via zinc-finger domains); interaction might be facilitated
CC       by TP53 oligomerization state (By similarity). Forms a ternary complex
CC       with ALDOB and G6PD; this interaction is direct. ALDOB stabilizes the
CC       complex inhibiting G6PD activity and keeping oxidative pentose
CC       phosphate metabolism in check. Interacts with MORN3; the interactions
CC       mediate post-transcriptional modifications of TP53 by MDM2 and SIRT1
CC       (By similarity). Interacts with HSPA9/MOT-2; the interaction promotes
CC       the degradation of TP53 (By similarity). {ECO:0000250|UniProtKB:P02340,
CC       ECO:0000250|UniProtKB:P04637, ECO:0000269|PubMed:8663025}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P04637}. Nucleus
CC       {ECO:0000250|UniProtKB:P04637}. Nucleus, PML body
CC       {ECO:0000250|UniProtKB:P04637}. Endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:P04637}. Mitochondrion matrix
CC       {ECO:0000250|UniProtKB:P04637}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000250|UniProtKB:P04637}.
CC       Note=Interaction with BANP promotes nuclear localization. Recruited
CC       into PML bodies together with CHEK2. Translocates to mitochondria upon
CC       oxidative stress. Translocates to mitochondria in response to mitomycin
CC       C treatment (By similarity). Competitive inhibition of TP53 interaction
CC       with HSPA9/MOT-2 by UBXN2A results in increased protein abundance and
CC       subsequent translocation of TP53 to the nucleus (By similarity).
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- DOMAIN: The N-terminal and C-terminal disordered regions undergo
CC       liquid-liquid phase separation (LLPS) following homotetramerization and
CC       activation. Post-translational modifications, such as phosphorylation
CC       or lactylation affect the ability to undergo LLPS.
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- DOMAIN: The nuclear export signal acts as a transcriptional repression
CC       domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56)
CC       correspond both to 9aaTAD motifs which are transactivation domains
CC       present in a large number of yeast and animal transcription factors.
CC       {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Phosphorylation on Ser residues mediates transcriptional
CC       activation. Phosphorylation at Ser-9 by HIPK4 increases repression
CC       activity on BIRC5 promoter (By similarity). Phosphorylated on Thr-18 by
CC       VRK1, which may prevent the interaction with MDM2. Phosphorylated on
CC       Ser-20 by CHEK2 in response to DNA damage, which prevents
CC       ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to
CC       reactive oxygen species (ROS), promoting p53/TP53-mediated apoptosis.
CC       Probably phosphorylated on by CDK7 in a CAK complex in response to DNA
CC       damage. Phosphorylated by HIPK1. Phosphorylated on Ser-390 following UV
CC       but not gamma irradiation. Stabilized by CDK5-mediated phosphorylation
CC       in response to genotoxic and oxidative stresses at Ser-15, leading to
CC       accumulation of p53/TP53, particularly in the nucleus, thus inducing
CC       the transactivation of p53/TP53 target genes. Phosphorylated at Ser-313
CC       and Ser-390 by CDK2 in response to DNA-damage (By similarity).
CC       Phosphorylation at Ser-15 is required for interaction with DDX3X and
CC       gamma-tubulin (By similarity). Phosphorylation at Ser-390 regulates its
CC       ability to undergo liquid-liquid phase separation by increasing
CC       fluidity of TP53/p53 condensates (By similarity). {ECO:0000250,
CC       ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Monomethylated at Lys-370 by SETD7, leading to stabilization and
CC       increased transcriptional activation. Monomethylated at Lys-368 by
CC       SMYD2, leading to decreased DNA-binding activity and subsequent
CC       transcriptional regulation activity. Lys-370 monomethylation prevents
CC       interaction with SMYD2 and subsequent monomethylation at Lys-368.
CC       Dimethylated at Lys-371 by EHMT1 and EHMT2. Monomethylated at Lys-380
CC       by KMT5A, promoting interaction with L3MBTL1 and leading to repress
CC       transcriptional activity. Demethylation of dimethylated Lys-368 by
CC       KDM1A prevents interaction with TP53BP1 and represses TP53-mediated
CC       transcriptional activation (By similarity). Monomethylated at Arg-331
CC       and dimethylated at Arg-333 and Arg-335 by PRMT5; methylation is
CC       increased after DNA damage and might possibly affect TP53 target gene
CC       specificity (By similarity). {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Sumoylated with SUMO1. Sumoylated at Lys-384 by UBC9 (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal
CC       degradation. Ubiquitinated by RFWD3, which works in cooperation with
CC       MDM2 and may catalyze the formation of short polyubiquitin chains on
CC       p53/TP53 that are not targeted to the proteasome. Ubiquitinated by
CC       MKRN1, which leads to proteasomal degradation. Deubiquitinated by
CC       USP10, leading to stabilize it. Ubiquitinated by TRIM24, RFFL, RNF34
CC       and RNF125, which leads to proteasomal degradation. Ubiquitination by
CC       TOPORS induces degradation. Deubiquitination by USP7, leading to
CC       stabilize it. Ubiquitinated by COP1, which leads to proteasomal
CC       degradation (By similarity). Ubiquitination and subsequent proteasomal
CC       degradation is negatively regulated by CCAR2 (By similarity).
CC       Polyubiquitinated by C10orf90/FATS, polyubiquitination is 'Lys-48'-
CC       linkage independent and non-proteolytic, leading to TP53 stabilization
CC       (By similarity). Polyubiquitinated by MUL1 at Lys-24 which leads to
CC       proteasomal degradation (By similarity). Deubiquitinated by USP3,
CC       leading to stabilization (By similarity). Ubiquitinated by MSL2,
CC       promoting its cytoplasmic localization (By similarity).
CC       {ECO:0000250|UniProtKB:P02340, ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Acetylation of Lys-380 by CREBBP enhances transcriptional
CC       activity. Acetylation of Lys-380 by EP300. Deacetylation of Lys-380 by
CC       SIRT1 impairs its ability to induce proapoptotic program and modulate
CC       cell senescence. Deacetylation by SIRT2 impairs its ability to induce
CC       transcription activation in a AKT-dependent manner. Acetylation at Lys-
CC       379 increases stability. Deacetylation at Lys-379 by SIRT6 decreases
CC       its stability, thereby regulating cell senescence. Acetylated at Lys-
CC       118 by KAT5, KAT6A and KAT8; regulating its ability to induce
CC       proapoptotic program. {ECO:0000250|UniProtKB:P04637}.
CC   -!- PTM: Lactylation by AARS1 prevents ability to undergo liquid-liquid
CC       phase separation (LLPS), thereby inhibiting transcription factor
CC       activity. {ECO:0000250|UniProtKB:P04637}.
CC   -!- DISEASE: Note=p53 is found in increased amounts in a wide variety of
CC       transformed cells. p53 is frequently mutated or inactivated in many
CC       types of cancer.
CC   -!- SIMILARITY: Belongs to the p53 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X13058; CAA31457.1; -; mRNA.
DR   EMBL; L07910; AAA41788.1; -; Genomic_DNA.
DR   EMBL; L07904; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07905; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07906; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07907; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07908; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; L07909; AAA41788.1; JOINED; Genomic_DNA.
DR   EMBL; U90328; AAB80959.1; -; mRNA.
DR   EMBL; BC081788; AAH81788.2; -; mRNA.
DR   EMBL; BC098663; AAH98663.1; -; mRNA.
DR   PIR; S02192; S02192.
DR   RefSeq; NP_112251.2; NM_030989.3.
DR   RefSeq; XP_006246656.1; XM_006246594.3.
DR   RefSeq; XP_006246657.1; XM_006246595.3.
DR   AlphaFoldDB; P10361; -.
DR   SMR; P10361; -.
DR   BioGRID; 246960; 11.
DR   DIP; DIP-46016N; -.
DR   IntAct; P10361; 5.
DR   MINT; P10361; -.
DR   STRING; 10116.ENSRNOP00000074031; -.
DR   iPTMnet; P10361; -.
DR   PhosphoSitePlus; P10361; -.
DR   PaxDb; 10116-ENSRNOP00000047840; -.
DR   Ensembl; ENSRNOT00000046490.4; ENSRNOP00000047840.2; ENSRNOG00000010756.8.
DR   Ensembl; ENSRNOT00055052973; ENSRNOP00055043774; ENSRNOG00055030460.
DR   Ensembl; ENSRNOT00060048932; ENSRNOP00060040833; ENSRNOG00060028077.
DR   Ensembl; ENSRNOT00065000476; ENSRNOP00065000426; ENSRNOG00065000306.
DR   Ensembl; ENSRNOT00065046290; ENSRNOP00065037969; ENSRNOG00065026731.
DR   GeneID; 24842; -.
DR   KEGG; rno:24842; -.
DR   UCSC; RGD:3889; rat.
DR   AGR; RGD:3889; -.
DR   CTD; 7157; -.
DR   RGD; 3889; Tp53.
DR   eggNOG; ENOG502QVY3; Eukaryota.
DR   GeneTree; ENSGT00950000183153; -.
DR   HOGENOM; CLU_019621_0_0_1; -.
DR   InParanoid; P10361; -.
DR   OMA; HKKGEPC; -.
DR   OrthoDB; 2902631at2759; -.
DR   PhylomeDB; P10361; -.
DR   TreeFam; TF106101; -.
DR   Reactome; R-RNO-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-RNO-2559585; Oncogene Induced Senescence.
DR   Reactome; R-RNO-2559586; DNA Damage/Telomere Stress Induced Senescence.
DR   Reactome; R-RNO-349425; Autodegradation of the E3 ubiquitin ligase COP1.
DR   Reactome; R-RNO-5689880; Ub-specific processing proteases.
DR   Reactome; R-RNO-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-RNO-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-RNO-6804754; Regulation of TP53 Expression.
DR   Reactome; R-RNO-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-RNO-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-RNO-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-RNO-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-RNO-6804760; Regulation of TP53 Activity through Methylation.
DR   Reactome; R-RNO-6811555; PI5P Regulates TP53 Acetylation.
DR   Reactome; R-RNO-69473; G2/M DNA damage checkpoint.
DR   Reactome; R-RNO-69481; G2/M Checkpoints.
DR   Reactome; R-RNO-69541; Stabilization of p53.
DR   Reactome; R-RNO-69895; Transcriptional activation of cell cycle inhibitor p21.
DR   Reactome; R-RNO-8852276; The role of GTSE1 in G2/M progression after G2 checkpoint.
DR   Reactome; R-RNO-8941855; RUNX3 regulates CDKN1A transcription.
DR   Reactome; R-RNO-9833482; PKR-mediated signaling.
DR   PRO; PR:P10361; -.
DR   Proteomes; UP000002494; Chromosome 10.
DR   Bgee; ENSRNOG00000010756; Expressed in thymus and 20 other cell types or tissues.
DR   ExpressionAtlas; P10361; baseline and differential.
DR   GO; GO:0005813; C:centrosome; ISS:UniProtKB.
DR   GO; GO:0000785; C:chromatin; IDA:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell.
DR   GO; GO:0043073; C:germ cell nucleus; ISO:RGD.
DR   GO; GO:0005759; C:mitochondrial matrix; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; ISS:UniProtKB.
DR   GO; GO:0016604; C:nuclear body; ISO:RGD.
DR   GO; GO:0016363; C:nuclear matrix; ISO:RGD.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0016605; C:PML body; IDA:RGD.
DR   GO; GO:0032991; C:protein-containing complex; ISO:RGD.
DR   GO; GO:0005657; C:replication fork; ISO:RGD.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IDA:ARUK-UCL.
DR   GO; GO:0035861; C:site of double-strand break; ISO:RGD.
DR   GO; GO:0005667; C:transcription regulator complex; IDA:RGD.
DR   GO; GO:0017053; C:transcription repressor complex; ISO:RGD.
DR   GO; GO:0071889; F:14-3-3 protein binding; ISO:RGD.
DR   GO; GO:0036310; F:ATP-dependent DNA/DNA annealing activity; ISS:UniProtKB.
DR   GO; GO:0003682; F:chromatin binding; ISO:RGD.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0005507; F:copper ion binding; ISS:UniProtKB.
DR   GO; GO:0001046; F:core promoter sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0097718; F:disordered domain specific binding; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; ISO:RGD.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISS:UniProtKB.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; ISO:RGD.
DR   GO; GO:0019899; F:enzyme binding; ISO:RGD.
DR   GO; GO:0140296; F:general transcription initiation factor binding; ISO:RGD.
DR   GO; GO:0042826; F:histone deacetylase binding; ISO:RGD.
DR   GO; GO:0035033; F:histone deacetylase regulator activity; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0097371; F:MDM2/MDM4 family protein binding; IPI:RGD.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; ISS:UniProtKB.
DR   GO; GO:0140677; F:molecular function activator activity; ISO:RGD.
DR   GO; GO:0003730; F:mRNA 3'-UTR binding; ISO:RGD.
DR   GO; GO:0002039; F:p53 binding; ISO:RGD.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; ISS:UniProtKB.
DR   GO; GO:0002020; F:protease binding; ISO:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:RGD.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; ISO:RGD.
DR   GO; GO:0051087; F:protein-folding chaperone binding; ISO:RGD.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; ISO:RGD.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; ISS:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; ISO:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ARUK-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:RGD.
DR   GO; GO:0001094; F:TFIID-class transcription factor complex binding; ISO:RGD.
DR   GO; GO:0000976; F:transcription cis-regulatory region binding; ISO:RGD.
DR   GO; GO:0001221; F:transcription coregulator binding; IPI:RGD.
DR   GO; GO:0044325; F:transmembrane transporter binding; IPI:RGD.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:RGD.
DR   GO; GO:0006915; P:apoptotic process; ISO:RGD.
DR   GO; GO:0097190; P:apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006914; P:autophagy; ISO:RGD.
DR   GO; GO:0002326; P:B cell lineage commitment; ISO:RGD.
DR   GO; GO:0048539; P:bone marrow development; ISO:RGD.
DR   GO; GO:0010659; P:cardiac muscle cell apoptotic process; ISO:RGD.
DR   GO; GO:0060411; P:cardiac septum morphogenesis; ISO:RGD.
DR   GO; GO:0008283; P:cell population proliferation; ISO:RGD.
DR   GO; GO:0072717; P:cellular response to actinomycin D; ISO:RGD.
DR   GO; GO:0071480; P:cellular response to gamma radiation; ISO:RGD.
DR   GO; GO:0042149; P:cellular response to glucose starvation; ISO:RGD.
DR   GO; GO:0034605; P:cellular response to heat; IEP:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:RGD.
DR   GO; GO:0071479; P:cellular response to ionizing radiation; ISO:RGD.
DR   GO; GO:0071417; P:cellular response to organonitrogen compound; IEP:RGD.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IMP:RGD.
DR   GO; GO:0071401; P:cellular response to triglyceride; IEP:RGD.
DR   GO; GO:0034644; P:cellular response to UV; ISO:RGD.
DR   GO; GO:0071494; P:cellular response to UV-C; ISO:RGD.
DR   GO; GO:0071466; P:cellular response to xenobiotic stimulus; ISO:RGD.
DR   GO; GO:0090398; P:cellular senescence; ISS:UniProtKB.
DR   GO; GO:0007417; P:central nervous system development; ISO:RGD.
DR   GO; GO:0021549; P:cerebellum development; ISO:RGD.
DR   GO; GO:0051276; P:chromosome organization; ISO:RGD.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0007623; P:circadian rhythm; ISO:RGD.
DR   GO; GO:0008340; P:determination of adult lifespan; ISO:RGD.
DR   GO; GO:0006974; P:DNA damage response; ISS:UniProtKB.
DR   GO; GO:0030330; P:DNA damage response, signal transduction by p53 class mediator; ISO:RGD.
DR   GO; GO:0006977; P:DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest; ISO:RGD.
DR   GO; GO:0006978; P:DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator; ISO:RGD.
DR   GO; GO:0006302; P:double-strand break repair; ISO:RGD.
DR   GO; GO:0009792; P:embryo development ending in birth or egg hatching; ISO:RGD.
DR   GO; GO:0048568; P:embryonic organ development; ISO:RGD.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0006983; P:ER overload response; ISO:RGD.
DR   GO; GO:0048144; P:fibroblast proliferation; ISO:RGD.
DR   GO; GO:0007369; P:gastrulation; ISO:RGD.
DR   GO; GO:0014009; P:glial cell proliferation; ISO:RGD.
DR   GO; GO:0019661; P:glucose catabolic process to lactate via pyruvate; ISO:RGD.
DR   GO; GO:0007507; P:heart development; ISO:RGD.
DR   GO; GO:0002244; P:hematopoietic progenitor cell differentiation; ISO:RGD.
DR   GO; GO:0060218; P:hematopoietic stem cell differentiation; ISO:RGD.
DR   GO; GO:0001701; P:in utero embryonic development; ISO:RGD.
DR   GO; GO:0072332; P:intrinsic apoptotic signaling pathway by p53 class mediator; ISO:RGD.
DR   GO; GO:0042771; P:intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator; ISO:RGD.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISO:RGD.
DR   GO; GO:1990144; P:intrinsic apoptotic signaling pathway in response to hypoxia; ISO:RGD.
DR   GO; GO:0043504; P:mitochondrial DNA repair; ISO:RGD.
DR   GO; GO:0000423; P:mitophagy; ISO:RGD.
DR   GO; GO:0031571; P:mitotic G1 DNA damage checkpoint signaling; ISO:RGD.
DR   GO; GO:0009299; P:mRNA transcription; ISO:RGD.
DR   GO; GO:0035264; P:multicellular organism growth; ISO:RGD.
DR   GO; GO:0070266; P:necroptotic process; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:ARUK-UCL.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:RGD.
DR   GO; GO:0008156; P:negative regulation of DNA replication; ISO:RGD.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISO:RGD.
DR   GO; GO:1903451; P:negative regulation of G1 to G0 transition; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0060253; P:negative regulation of glial cell proliferation; ISO:RGD.
DR   GO; GO:1904024; P:negative regulation of glucose catabolic process to lactate via pyruvate; ISO:RGD.
DR   GO; GO:1903799; P:negative regulation of miRNA processing; ISO:RGD.
DR   GO; GO:1901525; P:negative regulation of mitophagy; ISO:RGD.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0007406; P:negative regulation of neuroblast proliferation; ISO:RGD.
DR   GO; GO:1905856; P:negative regulation of pentose-phosphate shunt; ISO:RGD.
DR   GO; GO:0045861; P:negative regulation of proteolysis; ISO:RGD.
DR   GO; GO:2000378; P:negative regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:2000647; P:negative regulation of stem cell proliferation; ISO:RGD.
DR   GO; GO:0032211; P:negative regulation of telomere maintenance via telomerase; ISO:RGD.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; ISO:RGD.
DR   GO; GO:0007405; P:neuroblast proliferation; ISO:RGD.
DR   GO; GO:0051402; P:neuron apoptotic process; ISO:RGD.
DR   GO; GO:0006289; P:nucleotide-excision repair; ISS:UniProtKB.
DR   GO; GO:0097252; P:oligodendrocyte apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090403; P:oxidative stress-induced premature senescence; ISO:RGD.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; ISO:RGD.
DR   GO; GO:0045787; P:positive regulation of cell cycle; IMP:RGD.
DR   GO; GO:2000774; P:positive regulation of cellular senescence; ISO:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:ARUK-UCL.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IMP:RGD.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; ISO:RGD.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; ISO:RGD.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; ISO:RGD.
DR   GO; GO:0062100; P:positive regulation of programmed necrotic cell death; ISO:RGD.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0090200; P:positive regulation of release of cytochrome c from mitochondria; ISO:RGD.
DR   GO; GO:0045899; P:positive regulation of RNA polymerase II transcription preinitiation complex assembly; ISO:RGD.
DR   GO; GO:0070245; P:positive regulation of thymocyte apoptotic process; ISO:RGD.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0006606; P:protein import into nucleus; ISO:RGD.
DR   GO; GO:0008104; P:protein localization; ISO:RGD.
DR   GO; GO:0050821; P:protein stabilization; ISO:RGD.
DR   GO; GO:0051262; P:protein tetramerization; IEA:InterPro.
DR   GO; GO:0065003; P:protein-containing complex assembly; ISO:RGD.
DR   GO; GO:0007265; P:Ras protein signal transduction; ISO:RGD.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; ISO:RGD.
DR   GO; GO:0042981; P:regulation of apoptotic process; ISO:RGD.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:ARUK-UCL.
DR   GO; GO:1902749; P:regulation of cell cycle G2/M phase transition; ISO:RGD.
DR   GO; GO:0042127; P:regulation of cell population proliferation; ISO:RGD.
DR   GO; GO:2000772; P:regulation of cellular senescence; ISO:RGD.
DR   GO; GO:0043516; P:regulation of DNA damage response, signal transduction by p53 class mediator; ISO:RGD.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; ISO:RGD.
DR   GO; GO:2000269; P:regulation of fibroblast apoptotic process; ISO:RGD.
DR   GO; GO:0051453; P:regulation of intracellular pH; IMP:RGD.
DR   GO; GO:1902253; P:regulation of intrinsic apoptotic signaling pathway by p53 class mediator; ISO:RGD.
DR   GO; GO:1902108; P:regulation of mitochondrial membrane permeability involved in apoptotic process; ISO:RGD.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; ISO:RGD.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; ISO:RGD.
DR   GO; GO:0070243; P:regulation of thymocyte apoptotic process; ISO:RGD.
DR   GO; GO:0034103; P:regulation of tissue remodeling; ISO:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0001836; P:release of cytochrome c from mitochondria; ISO:RGD.
DR   GO; GO:0090399; P:replicative senescence; ISO:RGD.
DR   GO; GO:0043200; P:response to amino acid; IEP:RGD.
DR   GO; GO:0046677; P:response to antibiotic; ISO:RGD.
DR   GO; GO:0031000; P:response to caffeine; IEP:RGD.
DR   GO; GO:0034097; P:response to cytokine; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0010332; P:response to gamma radiation; ISO:RGD.
DR   GO; GO:0055093; P:response to hyperoxia; IEP:RGD.
DR   GO; GO:0002931; P:response to ischemia; ISO:RGD.
DR   GO; GO:0010038; P:response to metal ion; IEP:RGD.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEP:RGD.
DR   GO; GO:0006979; P:response to oxidative stress; IEP:RGD.
DR   GO; GO:0032526; P:response to retinoic acid; IEP:RGD.
DR   GO; GO:0009651; P:response to salt stress; ISO:RGD.
DR   GO; GO:0009411; P:response to UV; IEP:RGD.
DR   GO; GO:0010224; P:response to UV-B; IEP:RGD.
DR   GO; GO:0033552; P:response to vitamin B3; IEP:RGD.
DR   GO; GO:0010165; P:response to X-ray; IMP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0009303; P:rRNA transcription; ISO:RGD.
DR   GO; GO:0072331; P:signal transduction by p53 class mediator; ISO:RGD.
DR   GO; GO:0001756; P:somitogenesis; ISO:RGD.
DR   GO; GO:0007283; P:spermatogenesis; IMP:RGD.
DR   GO; GO:0072089; P:stem cell proliferation; ISO:RGD.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISO:RGD.
DR   GO; GO:0002360; P:T cell lineage commitment; ISO:RGD.
DR   GO; GO:0002309; P:T cell proliferation involved in immune response; ISO:RGD.
DR   GO; GO:0070242; P:thymocyte apoptotic process; ISO:RGD.
DR   GO; GO:0045815; P:transcription initiation-coupled chromatin remodeling; ISO:RGD.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; ISO:RGD.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0060333; P:type II interferon-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0016032; P:viral process; ISO:RGD.
DR   CDD; cd08367; P53; 1.
DR   Gene3D; 2.60.40.720; -; 1.
DR   Gene3D; 6.10.50.20; -; 1.
DR   Gene3D; 4.10.170.10; p53-like tetramerisation domain; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR012346; p53/RUNT-type_TF_DNA-bd_sf.
DR   InterPro; IPR011615; p53_DNA-bd.
DR   InterPro; IPR036674; p53_tetramer_sf.
DR   InterPro; IPR010991; p53_tetrameristn.
DR   InterPro; IPR013872; p53_transactivation_domain.
DR   InterPro; IPR002117; p53_tumour_suppressor.
DR   PANTHER; PTHR11447; CELLULAR TUMOR ANTIGEN P53; 1.
DR   PANTHER; PTHR11447:SF6; CELLULAR TUMOR ANTIGEN P53; 1.
DR   Pfam; PF00870; P53; 1.
DR   Pfam; PF08563; P53_TAD; 1.
DR   Pfam; PF07710; P53_tetramer; 1.
DR   PRINTS; PR00386; P53SUPPRESSR.
DR   SUPFAM; SSF47719; p53 tetramerization domain; 1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   PROSITE; PS00348; P53; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Apoptosis; Biological rhythms; Cell cycle;
KW   Cytoplasm; Cytoskeleton; DNA-binding; Endoplasmic reticulum;
KW   Isopeptide bond; Metal-binding; Methylation; Mitochondrion; Necrosis;
KW   Nucleus; Phosphoprotein; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Tumor suppressor; Ubl conjugation; Zinc.
FT   CHAIN           1..391
FT                   /note="Cellular tumor antigen p53"
FT                   /id="PRO_0000185712"
FT   DNA_BIND        100..290
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   REGION          1..318
FT                   /note="Interaction with CCAR2"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   REGION          1..47
FT                   /note="Transcription activation (acidic)"
FT   REGION          64..108
FT                   /note="Interaction with WWOX"
FT                   /evidence="ECO:0000250"
FT   REGION          65..90
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          98..368
FT                   /note="Interaction with HIPK1"
FT                   /evidence="ECO:0000250"
FT   REGION          98..298
FT                   /note="Required for interaction with ZNF385A"
FT                   /evidence="ECO:0000250"
FT   REGION          111..234
FT                   /note="Required for interaction with FBXO42"
FT                   /evidence="ECO:0000250"
FT   REGION          114..290
FT                   /note="Interaction with AXIN1"
FT                   /evidence="ECO:0000250"
FT   REGION          254..292
FT                   /note="Interaction with E4F1"
FT                   /evidence="ECO:0000250"
FT   REGION          271..278
FT                   /note="Interaction with DNA"
FT                   /evidence="ECO:0000250"
FT   REGION          281..324
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          317..358
FT                   /note="Interaction with HIPK2"
FT                   /evidence="ECO:0000250"
FT   REGION          323..354
FT                   /note="Oligomerization"
FT   REGION          350..391
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          357..361
FT                   /note="Interaction with USP7"
FT                   /evidence="ECO:0000250"
FT   REGION          366..385
FT                   /note="Basic (repression of DNA-binding)"
FT   MOTIF           303..319
FT                   /note="Bipartite nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           337..348
FT                   /note="Nuclear export signal"
FT                   /evidence="ECO:0000250"
FT   MOTIF           368..370
FT                   /note="[KR]-[STA]-K motif"
FT   COMPBIAS        281..298
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        304..318
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        350..366
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         174
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   BINDING         177
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   BINDING         236
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   BINDING         240
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   SITE            118
FT                   /note="Interaction with DNA"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         9
FT                   /note="Phosphoserine; by HIPK4"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         15
FT                   /note="Phosphoserine; by CDK5, PRPK, AMPK, NUAK1 and ATM"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         18
FT                   /note="Phosphothreonine; by CK1, VRK1 and VRK2"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         20
FT                   /note="Phosphoserine; by CHEK2, CK1 and PLK3"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         39
FT                   /note="Phosphoserine; by MAPKAPK5"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         118
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         118
FT                   /note="N6-lactoyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         137
FT                   /note="N6-lactoyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         181
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         267
FT                   /note="Phosphoserine; by AURKB"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         282
FT                   /note="Phosphothreonine; by AURKB"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         303
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         313
FT                   /note="Phosphoserine; by AURKA, CDK1 and CDK2"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         319
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P02340"
FT   MOD_RES         331
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         333
FT                   /note="Symmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         335
FT                   /note="Symmetric dimethylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         368
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         368
FT                   /note="N6-methyllysine; by SMYD2; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         370
FT                   /note="N6-methyllysine; by SETD7"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         371
FT                   /note="N6,N6-dimethyllysine; by EHMT1 and EHMT2; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         371
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         379
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         380
FT                   /note="N6,N6-dimethyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         380
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         380
FT                   /note="N6-methyllysine; by KMT5A; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   MOD_RES         390
FT                   /note="Phosphoserine; by CK2, CDK2 and NUAK1"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   CROSSLNK        24
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   CROSSLNK        289
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   CROSSLNK        290
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   CROSSLNK        349
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P04637"
FT   CROSSLNK        384
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VARIANT         103
FT                   /note="G -> S"
FT   VARIANT         256
FT                   /note="E -> G"
FT   CONFLICT        174
FT                   /note="C -> W (in Ref. 2; AAA41788)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   391 AA;  43451 MW;  E62522313A5C872F CRC64;
     MEDSQSDMSI ELPLSQETFS CLWKLLPPDD ILPTTATGSP NSMEDLFLPQ DVAELLEGPE
     EALQVSAPAA QEPGTEAPAP VAPASATPWP LSSSVPSQKT YQGNYGFHLG FLQSGTAKSV
     MCTYSISLNK LFCQLAKTCP VQLWVTSTPP PGTRVRAMAI YKKSQHMTEV VRRCPHHERC
     SDGDGLAPPQ HLIRVEGNPY AEYLDDRQTF RHSVVVPYEP PEVGSDYTTI HYKYMCNSSC
     MGGMNRRPIL TIITLEDSSG NLLGRDSFEV RVCACPGRDR RTEEENFRKK EEHCPELPPG
     SAKRALPTST SSSPQQKKKP LDGEYFTLKI RGRERFEMFR ELNEALELKD ARAAEESGDS
     RAHSSYPKTK KGQSTSRHKK PMIKKVGPDS D
//
